← board
SCYX
Scynexis, Inc.distress 5/10 · elevated risk$3.96-2%today-58% from 52w high
Lead: ADPKD
Revenue
pre-revenue
Liquidity
$59M
Runway
10.0 yrs
Shares 1y
+90%
Price & events
-34.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.3%
1D
-18.1%
1W
+4.1%
1M
-52.0%
3M
-34.6%
6M
-30.4%
1Y
-76.7%
2Y
-93.1%
5Y
-93.1%
All
Overview
- Market Cap
- $314.20M
- Volume
- 165.80K
- 52 Week Range
- $3.80 – $9.44
- Total Shares
- 79.44M
- Float Shares
- 7.69M
- Short %
- 3.91%
- % Held by Insiders
- 2.00%
- % Held by Institutions
- 49.42%
- RVOL
- 2.00x
- Beta
- 1.10
Pipeline stages · 1 programs
SCY-078, Fluconazole, Echinocandin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-11-07 | Phase 3 | SCY-078, Fluconazole, Echinocandinorphan | Candidiasis, Invasive, Candidemia | 68 | terminated |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 11
- 2H 2028Guided 55%readoutPhase 2SCY-770 · Phase 2 study completionSEC 8-K
- 2H 2027Guided 55%readoutPhase 2SCY-770 · Early efficacy readout from Phase 2 studySEC 8-K
- second half of 2027Guided 55%readoutPhase 2SCY-770 · Early efficacy readoutSEC 8-K
- Q4 2026Guided 70%trial initiationsecondaryPhase 2SCY-770 · Phase 2 trial initiationSEC 8-K
- Q3 2026Guided 70%readoutPhase 1SCY-247 · IV Phase 1 resultsSEC 8-K
- 2026-08-12earningsEarningsEarnings releaseyahoo
- 2026-03-31partnershipSCY-770 · Acquired global rights from Poxel for SCY-770, an AMPK activator for ADPKD.SEC 8-K
- 2026-03-30partnershipPXL-770 · Acquired PXL-770 from Poxel with upfront $8M and milestones up to $188MSEC 8-K
- Q4 2024regulatory submissionFiled (NDA/BLA)ibrexafungerp · Request to FDA to lift clinical hold on MARIO studySEC 8-K
- Q4 2024trial initiationsecondaryPhase 1SCY-247 · Phase 1 study initiationSEC 8-K
- 2024-07-31partnershipibrexafungerp · Completed FURI, CARES, NATURE studies and achieved $10M development milestone from GSKSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $34 (+748% upside) · 3 analysts
- 2025-10-28GuggenheimBuy
Competitors — ADPKD
- VRTXVERTEX PHARMACEUTICALS INC / MA$119.1B · D1
Recent news
- 2026-07-20Federated Hermes (SCYX) group discloses 4.03% Scynexis stake in amended 13G - Stock Titan
- 2026-07-15FEDERATED HERMES, INC. Acquires 55,207 Shares of SCYNEXIS Inc - GuruFocus
- 2026-07-08Federated Hermes (SCYX) files 13G/A showing 55,207 shares (4.45%) - Stock Titan
- 2026-07-06Enterprise value to EBIT forward of SCYNEXIS, Inc. – NASDAQ:SCYX - TradingView
- 2026-07-03SCYNEXIS (NASDAQ:SCYX) Is In A Strong Position To Grow Its Business - simplywall.st
- 2026-06-30SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK - GlobeNewswire
- 2026-06-30SCYNEXIS (NASDAQ: SCYX) director gets RSU and option awards - Stock Titan
- 2026-06-30SCYNEXIS (SCYX) director receives new stock and option awards - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.